



**Multimeric Biotherapeutics, Inc.**  
**(“MultimericBio”)**  
***“Unlocking the potential of the TNF SuperFamily Ligands”***

**Biotech veteran Marc Hertz becomes CEO of Multimeric Biotherapeutics, Inc.**

Dec. 7, 2008, San Diego, CA – Multimeric Biotherapeutics, Inc. announces the appointment of Marc Hertz, Ph.D. as its Chief Executive Officer. Dr. Hertz is also a Founder of the company and will serve as Chairman of Board.

Dr. Hertz is a seasoned biotech executive with extensive experience in developing vaccines for cancer and infectious diseases. He received his B.A. from Bowdoin College in Biology with High Honors and his Ph.D. in Immunology and Microbiology from the University of Colorado Health Sciences Center and the National Jewish Medical and Research Center. He then moved to Pharmexa [CSE: PHARMX] where he worked on vaccine design, development, and delivery. He rapidly rose to become a Senior Vice President of this 102 person company with an annual operating budget of \$31 million. In 2005, Pharmexa acquired most of the assets of Epimmune, Inc., a publically traded [NASDAQ: EPMN] biologics and immunotherapeutics company in San Diego, and Marc became the President and CEO of the combined company, Pharmexa-Epimmune, Inc. There, he directed company strategy, business development, investor relations, and participated in multiple rounds of public fundraising that generated approximately \$90 million in investments for the company.

For further details, visit the company’s website: [www.multimericbio.com](http://www.multimericbio.com)

**About Multimeric Biotherapeutics, Inc.**

Multimeric Biotherapeutics, Inc. is a biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. It uses its novel technology to create next-generation vaccines and tumor immunotherapies. More information is available at [www.multimericbio.com](http://www.multimericbio.com) . Contact us at [info@multimericbio.com](mailto:info@multimericbio.com)